Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products
- 1 May 2004
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 47 (5) , 844-852
Abstract
Aims/hypothesis Activation of the receptor for advanced glycation end products (RAGE) reportedly triggers cellular responses implicated in the pathogenesis of diabetes, such as increasing vascular cell adhesion molecule-1 (VCAM-1) expression on vascular endothelial cells and inducing TNF-α secretion by mononuclear cells. The objective of this study was to evaluate whether RAGE binding affinity of AGE-BSAs and cellular activation correlate. Methods To produce AGEs with varying glycation, bovine albumin AGEs were prepared with 500 mmol/l of glucose, fructose or ribose at times of incubation from 1 to 12 weeks. In addition, AGE-BSA was generated using either glyoxylic acid or glycolaldehyde. Cellular binding of the AGE-BSAs and the effect on endothelial cell VCAM-1 expression were studied in RAGE-expressing human microvascular endothelial cell line-4 cells. Induction of TNF-α secretion was assessed using RAGE-expressing human peripheral blood mononuclear cells (PBMCs). Results Cellular binding of the different AGE preparations correlated well with RAGE affinity. Interestingly, we found that the AGE preparations, which were essentially endotoxin free (≤0.2 ng/mg protein), were incapable of inducing VCAM-1 or TNF-α secretion regardless of RAGE binding affinity, AGE concentration or incubation time. In contrast, the reported RAGE ligand S100b was confirmed to induce VCAM-1 expression on endothelial cells and TNF-α secretion by PBMCs after 24 h of treatment. Conclusions/interpretation The results of this study suggest that AGE modification and high RAGE binding affinity are not sufficient to generate pro-inflammatory signalling molecules. Thus, RAGE binding affinity of AGE-BSAs does not seem to correlate with cellular activation. Our findings using AGEs with strong RAGE-binding properties indicate that AGEs may not uniformly play a role in cellular activation.Keywords
This publication has 36 references indexed in Scilit:
- Do atherosclerosis and type 2 diabetes share a common inflammatory basis?European Heart Journal, 2002
- AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expressionKidney International, 2002
- Endothelial Dysfunction in Diabetes MellitusSeminars in Thrombosis and Hemostasis, 2000
- N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene ExpressionJournal of Biological Chemistry, 1999
- RAGE Mediates a Novel Proinflammatory AxisCell, 1999
- Characterization of the Advanced Glycation End-Product Receptor Complex in Human Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 1999
- Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.Journal of Clinical Investigation, 1995
- N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue ProteinsBiochemistry, 1995
- HMEC-1: Establishment of an Immortalized Human Microvascular Endothelial Cell LineJournal of Investigative Dermatology, 1992
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990